Melinda D. Willard

TL;DR: Findings from a whole-genome sequencing study of 88 matched HCC tumor/normal pairs, 81 of which are Hepatitis B virus (HBV) positive, find beta-catenin to be the mostrequently mutated oncogene and TP53 the most frequently mutated tumor suppressor.

TL;DR: Novel genomic alterations are uncovered that elucidate the mechanisms of sensitivity and resistance to anti-EGFR therapy in metastatic CRC patients and show that PI3K/mTOR inhibition could rescue cetuximab resistance.

TL;DR: Although this study defined the LY3164530 MTD and pharmacokinetics on both schedules, significant toxicities associated with EGFR inhibition and lack of a potential predictive biomarker limit future development, Nonetheless, the results provide insight into the development of bispecific antibody therapy.

TL;DR: This multicenter, open-label, phase I clinical trial consisted of part A (dose escalation) and part B (dose confirmation) in patients with advanced/metastatic cancer to identify a recommended phase II dose (RP2D).

TL;DR: Preclinical data support the clinical evaluation of merestinib, a type II NTRK kinase inhibitor (NCT02920996), both in treatment naïve patients and in patients progressed on type I NTRk kinase inhibitors with acquired secondary G667C mutation in N TRK fusion bearing tumors.